Krakow, Poland – 3 June 2019 – Selvita, a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and development partner for the pharmaceutical and biotechnology industries, will present at the upcoming EFMC-ACSMEDI MedChem Frontiers 2019 Conference, taking place June 10-13, in Krakow.
Throughout the whole event, Selvita team will be involved in various activities.
Business Development Managers will be available at booth #5, to discuss Selvita’s capabilities in the area of integrated drug discovery services, and potential collaborations.
Dr. Anna Karawajczyk, Team Leader of Computational Chemistry at Selvita, will give a presentation: “DPD-inspired Small Heterocyclic Libraries Characterized as Novel LsrK Kinase Inhibitors: an Opportunity to Fight Antimicrobial Resistance” during the session showcasing Pharma Research Highlights in Poland. The presentation will take place on Wednesday, June 12, at 5:00 PM CEST.
Selvita will also present data from its research program demonstrating potential of novel atypical 5-HT6 receptor antagonists. The poster will be presented on Wednesday, June 12, at 5:15 PM CEST.
To contact Selvita’s delegates at this conference, please email us at email@example.com
The EFMC – ACSMEDI Medicinal Chemistry Frontiers is co-organised on a biennial basis, as a collaboration between the ACS (American Chemical Society) and the EFMC (European Federation for Medicinal Chemistry). The meeting is a key symposium in its field with traditionally around 300 participants, from industry and academia, and each edition takes place in a different European city, this year in Krakow, Poland. The EFMC – ACSMEDI Medicinal Chemistry Frontiers Meeting attracts a highly targeted audience composed of experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. The scientific program for this conference will feature a plenary session, followed by sessions covering the latest advances in medicinal chemistry.
Additional information is available on the conference website at
Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Selvita is headquartered in Krakow with offices in the U.S. and U.K. Ardigen, a provider of precision medicine and artificial intelligence services, and NodThera, a company developing a new class of medicines to treat chronic inflammation, were conceived, incubated and launched by Selvita. In March 2019, Selvita announced the intent to split its oncology development and research services divisions into separate companies.
Malgorzata Syjud (corporate)
+48 660 797 362